第一单位：
Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. prinamea@tcd.ie.;Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
作者：
Gary,Hannon [1]
;
Bethany J,Heaton [2]
;
Alexander,Plant-Hately [2]
;
Christopher,David [2]
;
Neill J,Liptrott [2]
;
Ainhoa,Egizabal [3]
;
Ana,Ayerdi-Izquierdo [3]
;
Noelia,Alvarez [3]
;
Oihane,Ibarrola [4]
;
Andres Arbona,Celaya [4]
;
Angel,Del Pozo Perez [4]
;
Nerea,Lazcanoiturburu [4]
;
Iris,Luzuriaga [4]
;
Fikirte Debebe,Zegeye [5]
;
Shanbeh,Zienolddiny-Narui [5]
;
An,Jacobs [6]
;
Alexandra,Van Driessche [6]
;
Inge,Nelissen [6]
;
Ibane,Abasolo [7]
;
Fernanda,Andrade [8]
;
Nora,Ventosa [9]
;
Elisabet,González-Mira [9]
;
Aida,Carreño [9]
;
Adriele,Prina-Mello [10]
作者单位：
Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. prinamea@tcd.ie.;Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
[1]
Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.;Centre of Excellence for Long-Acting Therapeutics, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.
[2]
TECNALIA, Basque Research and Technology Alliance (BRTA), Mikeletegi Pasealekua 2, 20009 Donostia-San Sebastián, Spain.
[3]
Biokeralty Research Institute AIE, Parque Tecnológico de Álava, Vitoria- Gasteiz, Álava, Spain.
[4]
National Institute of Occupational Health, Oslo, Norway.
[5]
Health department, Flemish Institute for Technological Research (VITO), Mol, Belgium.
[6]
Drug Delivery & Targeting, Vall d'Hebron Institute de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035, Barcelona, Spain.;Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain.;Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanobiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035, Barcelona, Spain.
[7]
Drug Delivery & Targeting, Vall d'Hebron Institute de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035, Barcelona, Spain.;Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain.
[8]
Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029, Madrid, Spain.;Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, 08193 Bellaterra, Spain.
[9]
Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. prinamea@tcd.ie.;Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.;Advanced Materials and Bioengineering Research (AMBER) Centre, CRANN Institute, Trinity College Dublin, Dublin, Ireland.
[10]
DOI
10.1039/d4nr02821j
PMID
39445396
发布时间
2024-11-21
换一批
